Related Experiment Video
Updated: Jun 28, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells
Talin Haritunians1, Saskia Gueller, James O'Kelly
1Division of Hematology/Oncology, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA 90048, USA.
Abstract:
LY573636-sodium is a promising anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo. Moreover, studies have shown that the compound is selectively toxic towards tumor cells over their normal counterparts. This targeted effect makes LY573636 a candidate for combined therapy regimens in patients with advanced or resistant cancers. We studied for the first time, the anti-tumor properties of LY573636 against a variety of human hematopoietic malignancies, including AML, B-ALL, large B-cell and mantle cell lymphoma cell lines. Cells were treated with the compound in vitro and its effect on cell proliferation, apoptosis and differentiation was determined. The cell lines underwent growth arrest in response to treatment with LY573636 in a dose-dependent manner. This antiproliferative activity was associated with the induction of apoptosis, loss of mitochondrial membrane potential and induction of reactive oxygen species. Furthermore, we showed that LY573636 was able to induce granulocytic/monocytic differentiation of HL60 and U937 cells. LY573636, as shown before in solid tumors, is effective in hematopoietic cell lines as well. These data suggest the use of LY573636 alone or in combination with conventional chemotherapeutic regimens in hematopoietic malignancies.
Insights
LY573636-sodium effectively halts the growth of hematopoietic malignancies, including leukemia and lymphoma, by inducing cell death and differentiation. This anti-tumor agent shows promise for treating blood cancers, alone or with chemotherapy.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- LY573636-sodium demonstrates anti-tumor activity against solid tumors, with selective toxicity towards cancer cells.
- Its targeted effect suggests potential in combination therapies for advanced or resistant cancers.
Purpose of the Study:
- To investigate the anti-tumor properties of LY573636 against human hematopoietic malignancies for the first time.
- To evaluate the compound's effects on cell proliferation, apoptosis, and differentiation in leukemia and lymphoma cell lines.
Main Methods:
- Human hematopoietic cell lines (AML, B-ALL, lymphoma) were treated with LY573636 in vitro.
- Assays measured cell proliferation, apoptosis, mitochondrial membrane potential, reactive oxygen species, and differentiation.
Main Results:
- LY573636 induced dose-dependent growth arrest and apoptosis in all tested cell lines.
- Treatment led to loss of mitochondrial membrane potential and increased reactive oxygen species.
- LY573636 promoted granulocytic/monocytic differentiation in HL60 and U937 cells.
Conclusions:
- LY573636 exhibits significant anti-tumor efficacy in hematopoietic cell lines, similar to its effects on solid tumors.
- The compound's ability to induce growth arrest, apoptosis, and differentiation supports its potential use in treating hematologic malignancies.
- LY573636 may be a valuable agent for monotherapy or combination therapy in patients with leukemia and lymphoma.